CSIMarket Company Name, Ticker, Suppliers, else..
 
Newamsterdam Pharma Company N v   (NASDAQ: NAMS)
 
Price: $25.2300 $0.31 1.244%
Day's High: $26.005300521850586 Week Perf: -5.82 %
Day's Low: $ 25.04 30 Day Perf: -8.42 %
Volume (M): 143,814 52 Wk High: $ 42.21
Volume (M$): $ 0 52 Wk Avg: $32.60
Open: $25.15 52 Wk Low: $23.05



 Market Capitalization (Millions $) 3,071
 Shares Outstanding (Millions) 122
 Employees 100
 Revenues (TTM) (Millions $) 23
 Net Income (TTM) (Millions $) -213
 Cash Flow (TTM) (Millions $) -297
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a late-stage biopharmaceutical firm developing obicetrapib, an oral, low-dose, once-daily CETP inhibitor designed to lower LDL cholesterol in patients with cardiometabolic diseases who have inadequate responses to current therapies. The company has conducted multiple Phase 3 trials demonstrating significant LDL-C reductions and is pursuing commercialization in the U.S. and Europe. It has partnered with Menarini for European market distribution. Additionally, the company is conducting a cardiovascular outcomes trial to evaluate obicetrapib's effect on major adverse cardiovascular events.


   Company Address: Gooimeer 2-35 Naarden 1411
   Company Phone Number: (0) 35 206 2971   Stock Exchange / Ticker: NASDAQ NAMS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Charting New Horizons in Cardiovascular Care Obicetrapibs Promise and NewAmsterdam Pharmas Strategic Strides,

Published Wed, Apr 30 2025 12:45 PM UTC

Unlocking Cardiovascular Breakthroughs: NewAmsterdam Pharma s Promising DevelopmentsNewAmsterdam Pharma, a late-stage clinical biopharmaceutical company, has captured the attention of the scientific community with its recent data presentations at the 93rd European Atherosclerosis Society (EAS) Congress. The company showcased new clinical and preclinical findings from its ph...
Stock Market Announcement

NewAmsterdam Pharma Enhances Leadership Team with Strategic Share Option Grants Amidst Promising Developments in Cardiovascular Medicines

Published Thu, Jan 9 2025 8:39 PM UTC

In an industry where innovation and talent acquisition go hand-in-hand, NewAmsterdam Pharma Company N.V. a trailblazer in cardiovascular treatments, has once again fortified its ranks with an assertive move. The Netherlands-based biopharmaceutical firm, listed on the Nasdaq under the symbol NAMS, recently announced the approval of inducement share options for new key hires, ...
Shares

NewAmsterdam Pharma Boosts Talent Roster with Share Options for Non-Executive Hires Amid Promising Cardiovascular Developments

Published Fri, Feb 7 2025 9:01 PM UTC

Interpreting NewAmsterdam Pharma s Strategic Inducement Grants: Implications for Shareholder Value and Future GrowthIn a significant strategic move, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company, has recently announced the approval of inducement share options to support its recruitment efforts. The company focuses on develop...
Management Announcement

NewAmsterdam Pharma Seeks Recovery Amid Financial Losses and Promising Clinical Trials for Obicetrapib,

Published Fri, Jan 10 2025 1:01 PM UTC

NewAmsterdam Pharma Looks Forward Amidst Financial Losses and Promising Cardiovascular ResearchBy CSI MarketAs NewAmsterdam Pharma Company N.V. strides into 2025, the company s ambitions remain remarkably high despite the turbulence reflected in its recent financial performance. With a reported cumulative net loss of $133 million by the third quarter of 2024 and a strik...
Clinical Study

Promising Horizons in Cardiovascular Disease Management The Impact of Obicetrapib on LDL-C Reduction and Adverse Card...

Published Mon, Dec 30 2024 9:24 AM UTC

: The management of cardiovascular disease (CVD) remains a predominant challenge in modern medicine, particularly among patients who exhibit elevated levels of low-density lipoprotein cholesterol (LDL-C) and for whom existing therapeutic options are inadequate. The recent pivotal BROADWAY and BROOKLYN Phase 3 clinical trials conducted by NewAmsterdam Pharma illuminate the po...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 136.09
Price to Sales (Expected) -
Price to Book 4.62
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.54
Working Capital Ratio 9.71
Leverage Ratio (MRQ) 0.1
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.79 $
Revenues (TTM) 0.19 $
Cash Flow (TTM) -
Cash 5.23 $
Book Value 5.47 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 225,650
Net Income per Employee (TTM) -2,127,330
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.03

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -1921.71 %
Net Margin (MRQ) -1593.45 %
Net Cash Flow Margin (MRQ) -1021.32 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Newamsterdam Pharma N V's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.